We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Submitted, not yet approved
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1 Study to evaluate the Pharmacokinetics, Safety and Tolerability of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow Nebulizer System (registered) in Normal Healthy Volunteers
Scientific title
A Phase 1 Study to evaluate the Pharmacokinetics, Safety and Tolerability of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow Nebulizer System (registered) in Normal Healthy Volunteers
Secondary ID [1] 302364 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Progressive, Fibrosing Interstitial Lung Diseases 319147 0
Idiopathic Pulmonary Fibrosis 319531 0
Condition category
Condition code
Respiratory 317107 317107 0 0
Other respiratory disorders / diseases

Study type
Description of intervention(s) / exposure
This is a placebo-controlled study of 3 doses of Nintedanib Solution for Inhalation (AP02) (0.25 mg/mL) administered using the eFlow (registered) nebulizer to assess the pharmacokinetics, safety and tolerability of AP02 in normal healthy volunteers (NHV) to be undertaken at a single site (Nucleus Network Melbourne).

Cohorts 1, 2, and 3 (NHV) (n = 2 placebo; n = 6 active in each cohort) will be run sequentially. Cohorts 1, 2, and 3 will receive a single ascending dose, at 0.5, 1, and 2 mg dose of AP02, respectively, administered once via inhalation using a single subject use eFlow nebulizer. Total administration time will vary with no administration expected to exceed 20 minutes. In each of these cohorts, the first 2 (sentinel) subjects (1 placebo/1 active) will be dosed initially. If no significant safety/tolerability events occur within 24 hours, the remaining 6 subjects in that cohort (1 placebo/5 active) will be dosed. A total of 24 subjects are expected to be enrolled and each subject may only participate in one cohort.

If forced expiratory volume in one second (FEV1) in two or more subjects in any ascending dose cohort falls by greater than 10% at 15 minutes post-dose, all subsequent subjects will be pretreated with (90-100 µg) of salbutamol. Subjects will remain in the phase 1 clinic for 24 hours post-dose and then participate in a follow-up visit 7 days after dosing. the study may proceed to the next ascending dose cohort if no significant safety/tolerability events occur following review and as confirmed by the Safety Review Committee.

Principal Investigator will oversee patient participation in the study. Specific training and procedures such as eFlow instructions for use will be outlined in the protocol and participant's informed consent form.

Study drug and eFlows will be shipped to the site pharmacy. Study drug will contain labeled vials packaged into individual kits for each subject. The designated unblinded Pharmacist at the site will dispense the kit (AP02 or placebo) to the blinded dose administrator for use based on the randomization. Further details are included in the 'Study Design' section.

The Investigator and Medical Monitor will oversee the safety of the subjects participating in the study. The Sponsor and CRO will be responsible for study operations.
Intervention code [1] 318651 0
Treatment: Drugs
Comparator / control treatment
Inhaled Placebo. Those assigned to placebo will receive a single dose of placebo that is volume equivalent to the AP02 dose. Placebo contains:
- 0.0125 mg/mL riboflavin
- 0.45% (4.5 mg/mL) sodium chloride
- 0.5 mM (0.1206 mg/mL) sodium saccharin dihydrate
- Water
Control group

Primary outcome [1] 325194 0
To evaluate the safety and tolerability of AP02 in normal healthy volunteers (NHV). Safety and tolerability will be assessed by reviewing the incidence and severity of adverse events, serious adverse events and suspected unexpected serious adverse reactions; clinically significant changes from pre-dose to post-dose in physical examination, vital signs, laboratory values, oximetry and spirometry results. Adverse events will be collected from the time of informed consent until the completion of the follow-up visit. Adverse events will be followed until event resolution and will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).
Timepoint [1] 325194 0
Immediately post-dose, at 24 hours post dose and at 7 days post dose
Secondary outcome [1] 387149 0
To determine the maximum tolerated dose (MTD) of AP02. The MTD will be evaluated in conjunction with the primary objective and assessed at the end of each cohort by the Safety Review Committee (SRC) which will consist of the Principal Investigator, Medical Monitor and a physician from Avalyn Pharma. The SRC will review the data for the following potential dose limiting events;
- Possible or probably drug-related moderate or severe adverse event
- Saturated oxygen (SaO2) less than 80% post-dose measured using pulse oximeter
- SaO2 decrease greater than 10% from baseline measured using pulse oximeter
- FEV1 decrease of greater than 15% measured using spirometry and symptomatic occurring after pretreatment with salbutamol

If the committee determines that a dose limiting event has occurred, the previous tolerated dose level will be the MTD. The committee may also recommend repeating a dose level or de-escalation of a dose level. Further if a dose limiting event occurs, the SRC may request the subsequent cohort is tested by adjusting the AP02 active concentration by dilution with a 0.125 mg/mL formulation.
Timepoint [1] 387149 0
Immediately post-dose and 24 hours post-dose
Secondary outcome [2] 387374 0
To determine the nintedanib plasma pharmacokinetics (PK) following delivery of a single dose of AP02. Analysis of plasma nintedanib concentrations will be completed with the following parameters to be calculated for each dose;
- Maximum Concentration (Cmax)
- Time to Peak Concentration (Tmax)
- Area Under the Curve (AUC)
- Estimated drug concentration from Time 0 to 24 Hours Post-Dose (AUC(0-24))
- Half-life (T1/12)
Timepoint [2] 387374 0
Analysis will be completed at pre-dose, 10 minutes, 30 minutes, 1, 2, 4, 6, 8 and 24 hours post-dosing

Key inclusion criteria
A subject must meet all of the following inclusion criteria to be eligible to enroll in the clinical trial:

Inclusion Criteria for all Cohorts:
1. Males or females 18 to 55 years
2. Female subjects must be:
• Of non-childbearing potential [surgically sterilized or post–menopausal (12 months with no menses without alternative medical cause)] OR
• Not pregnant, breast feeding or planning to become pregnant AND willing to comply with the medically acceptable contraceptive requirements of the study from Screening to at least 30 days after the last study drug administration.
3. Must be able to communicate with site personnel and to understand and voluntarily sign the Informed Consent Form (ICF).

Minimum age
18 Years
Maximum age
55 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
The presence of any of the following exclusion criteria excludes a subject from study enrollment:
Exclusion Criteria for all Cohorts:
1. History of previous allergy or sensitivity to nintedanib.
2. History of reactive airways disease (such as asthma or chronic obstructive pulmonary disease), cystic fibrosis, or bronchiectasis. Patients with fully resolved childhood asthma with no recurrences or medical needs as an adult are permitted.
3. History of bleeding disorders or currently being treated with anticoagulants.
4. Human Immunodeficiency Virus Positive Result (HIV+).
5. Active Hepatitis B or C.
6. Cigarette/e-Cigarette smoking or use of other nicotine or tobacco containing products within 7 days prior to study drug administration.
7. Positive for drugs of abuse or alcohol use at screening or admission to Phase 1 facility. A breathalyzer test will be used to screen for the presence of alcohol. A urine standard panel will be used to test for the following substances (with repeat testing for confirmation, as needed):
• Opiates
• Methadone
• Cocaine
• Tetrahydrocannabinol
• Benzodiazepines
• Amphetamines / Methamphetamines
• Barbiturates
• 3,4-methylenedioxy-methamphetamine
• Phencyclidine
8. Participation in a clinical study with administration of an investigational drug product within the previous 30 days, or 5 half-lives (t1/2) of the previously administered investigational product.
9. Donation of blood or significant blood loss within the 8 weeks prior to admission to Phase 1 facility.
10. Donation of plasma within the week prior to admission to Phase 1 facility.
11. Any other condition which in the view of the investigator is likely to interfere with the study or put the subject at risk.
12. Use of any medication in the opinion of the principal investigator that that might interact with study drug or may lead to abnormal chemistry of hematology tests.
13. Aspartate aminotransferase or alanine aminotransferase (AST or ALT) > upper limit of normal
14. Clinically significant abnormality in the opinion of the principal investigator in baseline hematology or chemistry tests.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Study drug assignment will be blinded to study subjects and study site personnel except for designated unblinded Pharmacist/s who will undertake subject randomization and dispensation against the provided randomization schedule. Unblinded Pharmacist/s will be located off-site to study subjects and have no contact with them.
Individual treatment disclosure envelopes (code-break envelopes) will also be provided to the unblinded Pharmacist. These code-break envelopes will be kept in a secure location) and the Investigator will be able to access these during the study for safety reasons. The code-break envelopes will be used by the Investigator if it is necessary to break the blind for an individual subject in an emergency. After completion of the study, all code-break envelopes will be destroyed with confirmation to Avalyn.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomization using a randomization table created by computer software (i.e. computerized sequence generation).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis
As this is not a powered efficacy study, no formal sample size calculations were performed. The number of subjects proposed per cohort is considered sufficient for an exploratory study to assess the PK and safety of nebulized nintedanib. A sample size of 24 subjects is planned for this study.
Intent-to-Treat (ITT)
The ITT population will comprise all subjects and will be based on the treatment assignment, regardless of which dose level the subject actually received.
Per-Protocol (PP)
The PP population will comprise all subjects who have no major protocol deviations. The details of major protocol deviations will be defined in the statistical analysis plan. The PP population will be identified prior to unblinding.
The PK population will comprise all dosed subjects who have nintedanib concentrations for PK profiling and parameter calculations. These will be based on the actual dose level received. Placebo subjects will not be included in this analysis.
The safety population will comprise all subjects who receive any amount of study drug and will be based on the cohort to which the subject was assigned.

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 17596 0
Nucleus Network - Melbourne
Recruitment postcode(s) [1] 31340 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 306795 0
Commercial sector/Industry
Name [1] 306795 0
Avalyn Pharma Pty Ltd
Address [1] 306795 0
Level 17 HWT Tower 40 City Road Southbank VIC 3006
Country [1] 306795 0
Primary sponsor type
Commercial sector/Industry
Avalyn Pharma Pty Ltd
Level 17 HWT Tower 40 City Road Southbank VIC 3006
Secondary sponsor category [1] 307346 0
Name [1] 307346 0
Address [1] 307346 0
Country [1] 307346 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 306953 0
Alfred Health Human Research Ethics Committee
Ethics committee address [1] 306953 0
The Alfred Hospital 55 Commercial Rd, Melbourne VIC 3004
Ethics committee country [1] 306953 0
Date submitted for ethics approval [1] 306953 0
Approval date [1] 306953 0
Ethics approval number [1] 306953 0

Brief summary
This is a placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of 3 doses of Nintedanib Solution for Inhalation (AP02) (0.25 mg/mL) administered using the eFlow nebulizer in normal healthy volunteers. Eligible subjects will be assigned to one of three cohorts, where they will receive a single dose of AP02 (or matching placebo) via inhalation for up to approximately 20 minutes.

The primary objective of this study is to evaluate the safety and tolerability of AP02, with this to be evaluated in each cohort by the Safety Review Committee and through review of the adverse events, physical examination, vital signs, laboratory, oximetry and spirometry values prior to and after dosing. The secondary objectives are to determine the maximum tolerated dose (MTD) of AP02, and the nintedanib plasma pharmacokinetics (PK) following delivery of a single dose of AP02.

Sentinel dosing will be employed for this single site study with a total of approximately 24 volunteers to be enrolled - up to 8 in each cohort with 2 sentinel subjects dose 24 hours before the remaining 6 subjects.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 105566 0
Dr Jason Lickliter
Address 105566 0
Nucleus Network, Level 5, Burnet Building, AMREP Precinct, 89 Commercial Rd, Melbourne, VIC 3004
Country 105566 0
Phone 105566 0
+61 3 9076 8960
Fax 105566 0
Email 105566 0
Contact person for public queries
Name 105567 0
Dr Bruce Montgomery
Address 105567 0
Avalyn Pharma Pty Ltd, Level 17 HWT Tower 40 City Road Southbank VIC 3006
Country 105567 0
Phone 105567 0
+61 398695922
Fax 105567 0
Email 105567 0
Contact person for scientific queries
Name 105568 0
Dr Bruce Montgomery
Address 105568 0
Avalyn Pharma Pty Ltd, Level 17 HWT Tower 40 City Road Southbank VIC 3006
Country 105568 0
Phone 105568 0
+61 398695922
Fax 105568 0
Email 105568 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
Individual results will not be shared. Only aggregate data through publications will be shared.
What supporting documents are/will be available?
No other documents available
Summary results
No Results